Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 5.43B +118.9% |
| Revenue (ttm) | 3.05B +7.6% |
| Net Income | 122.12M |
| EPS | 0.37 |
| Shares Out | 319.02M |
| PE Ratio | 45.86 |
| Forward PE | 16.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,553,755 |
| Open | 17.02 |
| Previous Close | 16.96 |
| Day's Range | 16.76 - 17.19 |
| 52-Week Range | 7.67 - 17.86 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 17.25 (+1.35%) |
| Earnings Date | Jul 30, 2026 |
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and res... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for AMRX stock is "Buy." The 12-month stock price target is $17.25, which is an increase of 1.35% from the latest price.
News
Amneal to Report Second Quarter 2026 Results on July 30, 2026
BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Th...
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
Eli Lilly (LLY), Regeneron (REGN), Amneal (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot progr...
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Zambon, Amneal Pharmaceuticals announce CHMP opinion recommending Hopledo
Zambon and Amneal Pharmaceuticals (AMRX) announced that the Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the granting of a marketing authorization by th...
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations
MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hope announce...
Amneal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is accelerating growth through biosimilars, specialty launches, and a major acquisition, with a robust pipeline and expanding manufacturing capacity. Strategic partnerships, notably with Pfizer, and disciplined capital allocation underpin long-term growth plans.
Amneal Pharmaceuticals announces interim results from ELEVATE-PD study
Amneal Pharmaceuticals (AMRX) announced new interim results from its ongoing Phase 4 ELEVATE-PD study, which are being presented at the Advanced Therapeutics in Movement & Related Disorders, or ATRMD,...
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEV...
Amneal Pharmaceuticals announces FDA approval of romidepsin injection solution
Amneal Pharmaceuticals (AMRX) announced that the FDA has approved the company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.
Amneal Pharmaceuticals announces FDA approval of romidepsin injection solution
Amneal Pharmaceuticals (AMRX) announced that the FDA has approved the company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity an...
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will ...
Amneal Pharmaceuticals price target raised to $16 from $15 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $16 from $15 and keeps an Overweight rating on the shares. The firm says it has…
Amneal Pharmaceuticals reports Q1 EPS 27c, consensus 17c
Reports Q1 revenue $722.52M, consensus $716.78M. “Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Ou...
Amneal Pharmaceuticals backs FY26 adjusted EPS view 95c-$1.05, consensus $1.00
Backs FY26 revenue view $3.05B-$3.15B, consensus $3.1B. Backs FY26 adjusted EBITDA view $740M-$770M. Backs FY26 capital expenditures view $110M.
Amneal Reports First Quarter 2026 Financial Results
‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preli...
Amneal Pharmaceuticals Transcript: AGM 2026
The meeting was conducted virtually, with all director nominees elected and all proposals approved. No questions were raised by stockholders, and official voting results will be announced after verification.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Proxy statement
Amneal Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Earnings Call Transcript: Q1 2026
Announced acquisition of Kashiv BioSciences, creating a global biosimilars leader with a robust pipeline and strong Q1 results. Raised 2026 guidance, with biosimilars expected to drive significant revenue and margin growth through 2030.
Amneal Pharmaceuticals Slides: Q1 2026
Amneal Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.
Amneal Pharmaceuticals Quarterly report: Q1 2026
Amneal Pharmaceuticals has published its Q1 2026 quarterly earnings report on April 22, 2026.